Inventor
KIRSHNER JESSICA R
US23 patents
Patents
23 patentsUS10772972B2Sep 15, 2020
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
REGENERON PHARMA44 citations97
US10738130B2Aug 11, 2020
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
REGENERON PHARMA50 citations97
US9302015B2Apr 5, 2016
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
REGENERON PHARMA82 citations97
US10179819B2Jan 15, 2019
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA25 citations93
US9475875B2Oct 25, 2016
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA14 citations92
US11155633B2Oct 26, 2021
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA9 citations85
US10550193B2Feb 4, 2020
Methods and antibody compositions for tumor treatment
REGENERON PHARMA8 citations84
US11485793B2Nov 1, 2022
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA4 citations83
US10941208B2Mar 9, 2021
Anti-MUC16 antibodies
REGENERON PHARMA6 citations83
US9545451B2Jan 17, 2017
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
REGENERON PHARMA6 citations83
US11434300B2Sep 6, 2022
Methods and antibody compositions for tumor treatment
REGENERON PHARMA2 citations73
US10738124B2Aug 11, 2020
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA3 citations73
US11633501B2Apr 25, 2023
Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
REGENERON PHARMA3 citations72
US10683354B2Jun 16, 2020
Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells
REGENERON PHARMA1 citations72
US10662244B2May 26, 2020
Methods for tumor treatment using CD3XCD20 bispecific antibody
REGENERON PHARMA2 citations72
US10106616B2Oct 23, 2018
Antagonist antibodies to human prolactin receptor (PRLR)
REGENERON PHARMA2 citations72
US9688764B2Jun 27, 2017
Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies
REGENERON PHARMA3 citations72
US10806780B2Oct 20, 2020
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
REGENERON PHARMA4 citations70
US12344677B2Jul 1, 2025
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA0 citations62
US11608380B2Mar 21, 2023
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA0 citations62
US10047160B2Aug 14, 2018
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA1 citations62
US12570764B2Mar 10, 2026
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA0 citations61
US12091460B2Sep 17, 2024
Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
REGENERON PHARMA0 citations55